Moderna Inc. and life-sciences company Thermo Fisher Scientific Inc. said Wednesday they have entered a long-term agreement to collaborate on large-scale manufacturing of the former's COVID-19 vaccine dubbed Spikevax and other therapies based on its mRNA technology. In a joint statement, the companies said they have already been working together to support Moderna's pipeline with Thermo Fisher providing clinical research and contract manufacturing services, including aseptic fill-finish services and packaging of the COVID vaccine. The expanded agreement will see them offer capacity for other fill-finish services and provide inspection, labeling and final packaging services. Moderna shares were up 1.6% premarket, while Thermo Fisher shares were not yet active.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
